MALIGNANT NEOPLASM PROGRESSION

Adverse reaction reported in 142,728 FDA reports across 70 drugs.

142,728
Total Reports
70
Drugs Involved
Pembrolizumab
Most Reported Drug

Drugs Associated with MALIGNANT NEOPLASM PROGRESSION

Drugs where "MALIGNANT NEOPLASM PROGRESSION" was reported as an adverse event.

# Drug Reports % of Total
1 Pembrolizumab 11,562
8.1%
2 Nivolumab 9,728
6.8%
3 Carboplatin 5,902
4.1%
4 Enzalutamide 5,440
3.8%
5 Everolimus 4,640
3.3%
6 Letrozole 4,379
3.1%
7 Paclitaxel 4,159
2.9%
8 Fulvestrant 4,113
2.9%
9 Capecitabine 3,901
2.7%
10 Ipilimumab 3,717
2.6%
11 Paclitaxel (Aibumin-Bound) 3,607
2.5%
12 Cabozantinib 3,344
2.3%
13 Cisplatin 3,162
2.2%
14 Osimertinib 3,142
2.2%
15 Pemetrexed Disodium 3,041
2.1%
16 Cyclophosphamide 3,040
2.1%
17 Cyclophosphamide For 3,040
2.1%
18 Docetaxel 2,720
1.9%
19 Bevacizumab 2,658
1.9%
20 Ribociclib 2,637
1.8%
21 Octreotide 2,458
1.7%
22 Palbociclib 2,324
1.6%
23 Lenvatinib 2,305
1.6%
24 Fluorouracil 2,089
1.5%
25 Doxorubicin 2,082
1.5%
26 Fluorouracil Cream, 0.5% 2,079
1.5%
27 Gemcitabine 2,044
1.4%
28 Trametinib 2,013
1.4%
29 Olaparib 2,008
1.4%
30 Etoposide 1,942
1.4%
31 Gefitinib 1,817
1.3%
32 Exemestane 1,794
1.3%
33 Dabrafenib 1,737
1.2%
34 Pazopanib 1,656
1.2%
35 Pemetrexed 1,641
1.1%
36 Oxaliplatin 1,621
1.1%
37 Durvalumab 1,474
1.0%
38 Trastuzumab 1,420
1.0%
39 Anastrozole 1,355
0.9%
40 Niraparib 1,352
0.9%
41 Goserelin 1,314
0.9%
42 Rucaparib 1,184
0.8%
43 Zoledronic Acid 1,154
0.8%
44 Cetuximab 1,083
0.8%
45 Abemaciclib 1,040
0.7%
46 Temozolomide 910
0.6%
47 Thalidomide 853
0.6%
48 Dasatinib 843
0.6%
49 Imatinib 797
0.6%
50 Erlotinib 766
0.5%
51 Nilotinib 719
0.5%
52 Ifosfamide 717
0.5%
53 Bicalutamide 712
0.5%
54 Lapatinib 559
0.4%
55 Irinotecan 528
0.4%
56 Alpelisib 502
0.4%
57 Abiraterone 404
0.3%
58 Bendamustine 379
0.3%
59 Axitinib 366
0.3%
60 Lanreotide 316
0.2%
61 Acalabrutinib 306
0.2%
62 Crizotinib 293
0.2%
63 Lutetium Lu 177 Vipivotide Tetraxetan 290
0.2%
64 Polatuzumab Vedotin 287
0.2%
65 Ado-Trastuzumab Emtansine 255
0.2%
66 Trifluridine / Tipiracil 227
0.2%
67 Encorafenib 225
0.2%
68 Brentuximab Vedotin 223
0.2%
69 Bleomycin 173
0.1%
70 Fam-Trastuzumab Deruxtecan-Nxki 160
0.1%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. The presence of a drug in this list does not mean the drug caused malignant neoplasm progression. Always consult your healthcare provider.